• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation (Amendment)

    2/14/24 10:23:19 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADPT alert in real time by email
    SC 13G/A 1 sayw24021407_13ga.htm


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-
    1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2
    UNDER THE SECURITIES EXCHANGE ACT OF 1934*
     
    (Amendment No. 3)
     
    Adaptive Biotechnologies Corporation
    (Name of Issuer)
     
    Common stock
    (Title of Class of Securities)
     
    00650F109
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☐ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
        ☒ Rule 13d-1(d)**
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    ** This Schedule 13G, originally filed by the Reporting Persons on February 11, 2020 and amended on February 16, 2021 and February 14, 2022, is required to be filed pursuant to Rule 13d-1(d) under the Securities Exchange Act of 1934 (the “Act”).  However, prior versions of this Schedule 13G inadvertently checked the box for Rule 13d-1(c) instead of Rule 13d-1(d).
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Act or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    CUSIP No. 00650F109
    13G
    Page 2 of 17 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Investors LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    29,993,708
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    29,993,708
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    29,993,708
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    20.7%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     
     

    CUSIP No. 00650F109
    13G
    Page 3 of 17 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Performance LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    22,002,189
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    22,002,189
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    22,002,189
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    15.2%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No. 00650F109
    13G
    Page 4 of 17 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Equities II LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    440,046
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    440,046
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    440,046
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.3%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     


    CUSIP No. 00650F109
    13G
    Page 5 of 17 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Equities Master Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    21,562,143
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    21,562,143
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    21,562,143
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    14.9%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    CUSIP No. 00650F109
    13G
    Page 6 of 17 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Long Fund GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    7,991,519
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    7,991,519
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    7,991,519
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.5%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No. 00650F109
    13G
    Page 7 of 17 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Long Fund Master Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    7,991,519
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    7,991,519
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    7,991,519
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.5%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    CUSIP No. 00650F109
    13G
    Page 8 of 17 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    O. Andreas Halvorsen
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Norway
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    29,993,708
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    29,993,708
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    29,993,708
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    20.7%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No. 00650F109
    13G
    Page 9 of 17 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    David C. Ott
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    29,993,708
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    29,993,708
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    29,993,708
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    20.7%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No. 00650F109
    13G
    Page 10 of 17 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Rose S. Shabet
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    29,993,708
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    29,993,708
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    29,993,708
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)*
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    20.7%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No. 00650F109
    13G
    Page 11 of 17 Pages
    Item 1(a).
    Name of Issuer:
     
     Adaptive Biotechnologies Corporation
     
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
     
     1165 Eastlake Avenue East
     Seattle, Washington 98109
     
    Item 2(a).
    Name of Person Filing:
     
     Viking Global Investors LP (“VGI”),
     Viking Global Performance LLC (“VGP”),
     Viking Global Equities II LP (“VGEII”),
     Viking Global Equities Master Ltd. (“VGEM”),
     Viking Long Fund GP LLC (“VLFGP”),
     Viking Long Fund Master Ltd. (“VLFM”),
     O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the “Reporting Persons”)
     
    Items 2(b).
    Address of Principal Business Office or, if none, Residence:
     
     The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.
     
    Items 2(c).
    Citizenship:
     
     VGI and VGEII are Delaware limited partnerships; VGP and VLFGP are Delaware limited liability companies; VGEM and VLFM are Cayman Islands exempted companies; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.
     
    Item 2(d).
    Titles of Classes of Securities:
     
     Common stock (“Common Stock”)
     
    Item 2(e).
    CUSIP NUMBER: 00650F109

    Item 3.
    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
     

    (a)
    ☐ Broker or dealer registered under Section 15 of the Exchange Act

    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Exchange Act

    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act

    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940

    (e)
    ☐ Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940: see Rule 13d-1(b)(1)(ii)(E)

    (f)
    ☐ Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F)

    (g)
    ☐ Parent holding company, in accordance with Rule 13d-1(b)(1)(ii)(G).

    (h)
    ☐ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.

    (i)
    ☐ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.

    (j)
    ☐ Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

    (k)
    ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).


    CUSIP No. 00650F109
    13G
    Page 12 of 17 Pages
    Item 4.
    Ownership
     
    The percentages set forth herein are based on 144,772,751 shares of Common Stock outstanding as of November 3, 2023, as reported by the Issuer in its quarterly report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (the “Commission”) on November 9, 2023.
     
    A. VGI
     
     
    (a)
    Amount beneficially owned: 29,993,708
         
     
    (b)
    Percent of Class: 20.7%
         
     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0
     
    (ii)
    Shared power to vote or to direct the vote: 29,993,708
     
    (iii)
    Sole power to dispose or to direct the disposition of: 0
     
    (iv)
    Shared power to dispose or to direct the disposition of: 29,993,708

    VGI provides managerial services to VGEII, VGEM and VLFM. VGI has the authority to dispose of and vote the shares of Common Stock directly owned by VGEII, VGEM and VLFM. VGI does not directly own any shares of Common Stock.
     
    Based on Rule 13d-3 of the Act”), VGI may be deemed to beneficially own the shares of Common Stock directly held by VGEII, VGEM and VLFM.
     
    VGI beneficially owns 29,993,708 shares of Common Stock consisting of (i) 440,046 shares of Common Stock directly and beneficially owned by VGEII, (ii) 21,562,143 shares of Common Stock directly and beneficially owned by VGEM and (iii) 7,991,519 shares of Common Stock directly and beneficially owned by VLFM.
     
    B. VGP
     
    (a)
    Amount beneficially owned: 22,002,189

     
    (b)
    Percent of Class: 15.2%

     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0
     
    (ii)
    Shared power to vote or to direct the vote: 22,002,189
     
    (iii)
    Sole power to dispose or to direct the disposition of: 0
     
    (iv)
    Shared power to dispose or to direct the disposition of: 22,002,189

    VGP, as the general partner of VGEII, has the authority to dispose of and vote the shares of Common Stock directly owned by VGEII. VGP serves as investment manager to VGEM and has the authority to dispose of and vote the shares of Common Stock directly owned by VGEM. VGP does not directly own any shares of Common Stock.
     
    Based on Rule 13d-3 of the Act, VGP may be deemed to beneficially own the shares of Common Stock directly held by VGEII and VGEM.
     
    VGP beneficially owns 22,002,189 of Common Stock consisting of (i) 440,046 shares of Common Stock directly and beneficially owned by VGEII and (ii) 21,562,143 shares of Common Stock directly and beneficially owned by VGEM.
     

    CUSIP No. 00650F109
    13G
    Page 13 of 17 Pages
    C. VGEII
     
     
    (a)
    Amount beneficially owned: 440,046
         
     
    (b)
    Percent of Class: 0.3%
         
     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0
     
    (ii)
    Shared power to vote or to direct the vote: 440,046
     
    (iii)
    Sole power to dispose or to direct the disposition of: 0
     
    (iv)
    Shared power to dispose or to direct the disposition of: 440,046

    VGEII has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its general partner, VGP, and by VGI, an affiliate of VGP, which provides managerial services to VGEII.
    D. VGEM
     
     
    (a)
    Amount beneficially owned: 21,562,143
         
     
    (b)
    Percent of Class: 14.9%
         
     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0
     
    (ii)
    Shared power to vote or to direct the vote: 21,562,143
     
    (iii)
    Sole power to dispose or to direct the disposition of: 0
     
    (iv)
    Shared power to dispose or to direct the disposition of: 21,562,143

    VGEM has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its investment manager, VGP, and by VGI, an affiliate of VGP, which provides managerial services to VGEM. Viking Global Equities LP (a Delaware limited partnership) and Viking Global Equities III Ltd. (a Cayman Islands exempted company), through its investment in VGE III Portfolio Ltd. (a Cayman Islands exempted company), invest substantially all of their assets through VGEM.
     
    E. VLFGP
     
     
    (a)
    Amount beneficially owned: 7,991,519
         
     
    (b)
    Percent of Class: 5.5%
         
     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0
     
    (ii)
    Shared power to vote or to direct the vote: 7,991,519
     
    (iii)
    Sole power to dispose or to direct the disposition of: 0
     
    (iv)
    Shared power to dispose or to direct the disposition of: 7,991,519

    VLFGP serves as the investment manager of VLFM and has the authority to dispose of and vote the shares of Common Stock directly owned by VLFM. VLFGP does not directly own any shares of Common Stock.
     
    Based on Rule 13d-3 of the Act, VLFGP may be deemed to beneficially own the shares of Common Stock directly held by VLFM.


    CUSIP No. 00650F109
    13G
    Page 14 of 17 Pages
    F. VLFM
     
     
    (a)
    Amount beneficially owned: 7,991,519
         
     
    (b)
    Percent of Class: 5.5%
         
     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0
     
    (ii)
    Shared power to vote or to direct the vote: 7,991,519
     
    (iii)
    Sole power to dispose or to direct the disposition of: 0
     
    (iv)
    Shared power to dispose or to direct the disposition of: 7,991,519

    VLFM has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its investment manager, VLFGP, and by VGI, an affiliate of VLFGP, which provides managerial services to VLFM. Viking Long Fund LP (a Delaware limited partnership) and Viking Long Fund III Ltd. (a Cayman Islands exempted company), through its investment in Viking Long Fund Intermediate L.P. (a Cayman Islands limited partnership), invest substantially all of their assets through VLFM.
     
    G. O. Andreas Halvorsen, David C. Ott and Rose S. Shabet
     
     
    (a)
    Amount beneficially owned: 29,993,708
         
     
    (b)
    Percent of Class: 20.7%
         
     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote: 0
     
    (ii)
    Shared power to vote or to direct the vote: 29,993,708
     
    (iii)
    Sole power to dispose or to direct the disposition of: 0
     
    (iv)
    Shared power to dispose or to direct the disposition of: 29,993,708

    Mr. Halvorsen, Mr. Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI), VGP and VLFGP, have shared authority to dispose of and vote the shares of Common Stock beneficially owned by VGI, VGP and VLFGP. None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly owns any shares of Common Stock.
     
    Based on Rule 13d-3 of the Act, each may be deemed to beneficially own the shares of Common Stock directly held by VGEII, VGEM and VLFM.
     
    Mr. Halvorsen, Mr. Ott and Ms. Shabet each beneficially own 29,993,708 shares of Common Stock consisting of (i) 440,046 shares of Common Stock directly and beneficially owned by VGEII, (ii) 21,562,143 shares of Common Stock directly and beneficially owned by VGEM and (iii) 7,991,519 shares of Common Stock directly and beneficially owned by VLFM.
     
    Item 5.
    Ownership of Five Percent or Less of a Class.
     
    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    The response to Item 4 is incorporated by reference herein.
     

    CUSIP No. 00650F109
    13G
    Page 15 of 17 Pages
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
     
    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group.
     
    Not applicable.
     
    Item 9.
    Notice of Dissolution of Group.
     
    Not applicable.
     
    Item 10.
    Certification. (if filing pursuant to Rule 13d-1(d))
     
    Not applicable.
     

    CUSIP No. 00650F109
    13G
    Page 16 of 17 Pages
    SIGNATURES
     
    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
     
    Dated: February 14, 2024
     
     
    By:
    /s/ Scott M. Hendler
     
     
    Name: Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
       
     
    By:
    /s/ Scott M. Hendler
     
     
    Name: Scott M. Hendler on behalf of David C. Ott (2)
       
     
    By:
    /s/ Scott M. Hendler
     
     
    Name: Scott M. Hendler on behalf of Rose S. Shabet (3)

    (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
     
    (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737).
     
    (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).
     

    CUSIP No. 00650F109
    13G
    Page 17 of 17 Pages
    EXHIBIT A - JOINT FILING AGREEMENT
     
    This joint filing agreement is made and entered into as of this 14th day of February, 2024, by and among Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities II LP, Viking Global Equities Master LTD., Viking Long Fund GP LLC, Viking Long Fund Master LTD., O. Andreas Halvorsen, David C. Ott and Rose S. Shabet.

    The parties to this Agreement hereby agree to prepare jointly and file timely (and otherwise to deliver as appropriate) all filings on any Forms 3, 4, or 5 or Schedules 13D or 13G, and any and all amendments thereto and any other documents relating thereto (collectively, the “Filings”) as required to be filed pursuant to the Securities Exchange Act of 1934, as amended. The parties to this Agreement further agree and covenant that each will fully cooperate with such other parties in the preparation, timely filing, and delivery of all such Filings.
     
    IN WITNESS WHEREOF, the parties hereto have executed this agreement as of the date first set forth above.
     
    Dated: February 14, 2024

     
    By:
    /s/ Scott M. Hendler
     
    Name: Scott M. Hendler on behalf of O. Andreas Halvorsen (1)

     
    By:
    /s/ Scott M. Hendler
     
    Name: Scott M. Hendler on behalf of David C. Ott (2)

     
    By:
    /s/ Scott M. Hendler
     
    Name: Scott M. Hendler on behalf of Rose S. Shabet (3)

    (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
     
    (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737).
     
    (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).
     


    Get the next $ADPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADPT

    DatePrice TargetRatingAnalyst
    3/21/2025$9.00Neutral → Buy
    Goldman
    7/5/2023$15.00Overweight
    JP Morgan
    1/5/2023$15.00Sector Outperform
    Scotiabank
    12/21/2022$7.50 → $14.00Neutral → Overweight
    Piper Sandler
    8/25/2022$8.00Underperform
    Credit Suisse
    6/3/2022$7.50Neutral
    Piper Sandler
    2/16/2022$40.00 → $32.00Buy
    BofA Securities
    2/16/2022$75.00 → $50.00Overweight
    JP Morgan
    More analyst ratings

    $ADPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

      SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025. "We had a strong start to 2025 with 34% MRD revenue growth, driven by continued acceleration in clonoSEQ test volume and disciplined execution," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "This performance highlights the scalability of our MRD business and the growing momentum behind it. As a resul

      5/1/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

      SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours

      4/10/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

      SEATTLE, April 08, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its Molecular Diagnostic Services Program (MolDX), has expanded coverage of clonoSEQ® to include single time point testing to monitor for recurrence in patients with a history of mantle cell lymphoma (MCL). This expanded coverage is in addition to the existing Medicare episode payment structure for clonoS

      4/8/25 8:00:00 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

      SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Tycho Peterson as chief financial officer (CFO). Mr. Peterson brings several decades of financial leadership and experience within the life science and diagnostic industries. "Tycho has been a leader in this space over the last two decades, during which disruptive technologies such as genomic sequencing and artificial intelligence have driven a complete paradigm shift in diagnostics and precision medic

      3/9/22 7:00:00 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer

      SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Nitin Sood to the newly created position of chief commercial officer, effective immediately. Nitin brings more than 15 years of proven commercial experience at leading life sciences and diagnostics companies, most recently at Guardant Health. "Adaptive has set the stage for commercial success with well-defined growth strategies and a solid pipeline for our current research and diagnostic products. Nit

      8/4/21 4:15:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Financials

    Live finance-specific insights

    See more
    • Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

      SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025. "We had a strong start to 2025 with 34% MRD revenue growth, driven by continued acceleration in clonoSEQ test volume and disciplined execution," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "This performance highlights the scalability of our MRD business and the growing momentum behind it. As a resul

      5/1/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

      SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours

      4/10/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

      SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. "2024 was a year of strong execution, marked by key catalysts achieved in our MRD business and advancements in our Immune Medicine programs. Our MRD revenue grew by 42%, with a 35% increase in clonoSEQ test volume, and we nominated a lead autoimmune indication within our Immune Medicine business," said Chad

      2/11/25 4:05:00 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Adaptive Biotechnologies Corporation

      10-Q - Adaptive Biotechnologies Corp (0001478320) (Filer)

      5/1/25 4:30:23 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptive Biotechnologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)

      5/1/25 4:15:13 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Adaptive Biotechnologies Corporation

      DEFA14A - Adaptive Biotechnologies Corp (0001478320) (Filer)

      4/29/25 4:07:22 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Adaptive Biotechnologies Corporation

      SC 13G - Adaptive Biotechnologies Corp (0001478320) (Subject)

      11/13/24 4:30:24 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

      SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)

      11/13/24 9:00:21 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

      SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)

      11/12/24 1:30:57 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Piskel Kyle sold $17,149 worth of shares (1,929 units at $8.89), decreasing direct ownership by 0.71% to 269,581 units (SEC Form 4)

      4/A - Adaptive Biotechnologies Corp (0001478320) (Issuer)

      5/20/25 7:46:28 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Piskel Kyle was granted 7,815 shares and sold $17,149 worth of shares (1,929 units at $8.89), increasing direct ownership by 2% to 277,396 units (SEC Form 4)

      4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

      5/19/25 7:59:39 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Robins Harlan S exercised 68,412 shares at a strike of $6.32 and sold $502,828 worth of shares (68,412 units at $7.35) (SEC Form 4)

      4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

      5/5/25 5:27:53 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

      For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.  “Today’s authorization further und

      3/5/21 10:37:33 PM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Adaptive Biotechnologies upgraded by Goldman with a new price target

      Goldman upgraded Adaptive Biotechnologies from Neutral to Buy and set a new price target of $9.00

      3/21/25 8:00:43 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan resumed coverage on Adaptive Biotechnologies with a new price target

      JP Morgan resumed coverage of Adaptive Biotechnologies with a rating of Overweight and set a new price target of $15.00

      7/5/23 7:14:22 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scotiabank initiated coverage on Adaptive Biotechnologies with a new price target

      Scotiabank initiated coverage of Adaptive Biotechnologies with a rating of Sector Outperform and set a new price target of $15.00

      1/5/23 7:29:02 AM ET
      $ADPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care